Takeda news

OSAKA, Japan, December 2, 2008 --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced that it is to begin construction of new research facilities which straddle the border of the cities of Fujisawa and Kamakura in Kanagawa Prefecture, Japan.

OSAKA, Japan, November 26, 2008 --- Takeda Pharmaceutical Company Limited (“Takeda”) announced that its Board of Directors resolved today acquisition of its own shares under Article 156 of the Corporation Law of Japan, as applied pursuant to Article 165 (3) of the Corporation Law, as detailed below:

Osaka, Japan, November 26, 2008 --- Takeda Pharmaceutical Company Limited (“Takeda”) announced today that it completed acquisition of its own shares in the market, which was resolved by its Board of Directors on October 20, 2008.

Osaka, Japan, November 21, 2008 --- Takeda Pharmaceutical Company Limited (Takeda) today announced that Takeda Global Research & Development Centre (Europe), Ltd. submitted a marketing authorization application for a prolonged-release formulation of its combination treatment for type 2 diabetes, Competact® (pioglitazone HCI and metfomin HCI) to the European Medicines Agency (EMEA).

THOUSAND OAKS, Calif. (Nov.

OSAKA, Japan, November 4, 2008 --- Takeda Pharmaceutical Company Limited ("Takeda") announced that its Board of Directors resolved today revision to increase the interim and planned annual dividends per share for the fiscal year ending March 31, 2009.

Osaka, Japan, October 30, 2008 -Takeda Pharmaceutical Company Limited ("Takeda") announced today that it filed a New Drug Application to the Ministry of Health, Labour and Welfare for a fixed dose combination tablet of Actos® (generic name: pioglitazone HCI) with metformin for the treatment of type 2 diabetes.

OSAKA, Japan, October 20, 2008 --- Takeda Pharmaceutical Company Limited (“Takeda”) announced that its Board of Directors resolved today acquisition of its own shares under Article 156 of the Corporation Law of Japan, as applied pursuant to Article 165 (3) of the Corporation Law, as detailed below:

Osaka, Japan, October 20, 2008 - Takeda Pharmaceutical Company Limited (“Takeda”) today announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary received notification from the U.S. Food and Drug Administration (FDA) that the agency will not be able to complete its review of the TAK-390MR New Drug Application (NDA) by the original Prescription Drug User Fee Act (PDUFA) date in October, 2008.